Cellectis (CLLS) Net Cash Flow Growth (3y) (2018 - 2026)
Cellectis (CLLS) Net Cash Flow Growth (3y) (2018 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-13.44% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Cellectis |
17.40 Bn |
17.21 Bn |
- |
-47.11% |
| Date | Value |
|---|
| Mar 31, 2026 |
-47.11% |
| Dec 31, 2025 |
36.22% |
| Sep 30, 2025 |
32.56% |
| Jun 30, 2025 |
-44.09% |
| Mar 31, 2025 |
17.13% |
| Dec 31, 2024 |
25.76% |
| Sep 30, 2024 |
32.69% |
| Jun 30, 2024 |
-15.60% |
| Mar 31, 2024 |
24.12% |
| Dec 31, 2023 |
103.28% |
| Sep 30, 2023 |
-32.27% |
| Jun 30, 2023 |
65.91% |
| Mar 31, 2023 |
44.63% |
| Dec 31, 2022 |
-32.78% |
| Sep 30, 2022 |
15.04% |
| Jun 30, 2022 |
3.49% |
| Mar 31, 2022 |
-2.07% |
| Dec 31, 2021 |
-14.41% |
| Sep 30, 2021 |
-107.46% |
| Jun 30, 2021 |
-44.67% |
